Literature DB >> 1577057

Polymorphism of debrisoquine oxidation in New Zealand Caucasians.

S Wanwimolruk1, J R Denton, D G Ferry, M Beasley, J R Broughton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1577057     DOI： 10.1007/bf00266364

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  13 in total

1.  Oxidation phenotyping in Chinese and Malay populations.

Authors:  E J Lee; Y P Nam; G N Hee
Journal:  Clin Exp Pharmacol Physiol       Date:  1988-11       Impact factor: 2.557

2.  Low frequency of slow debrisoquine hydroxylation in a native Chinese population.

Authors:  Y C Lou; L Ying; L Bertilsson; F Sjöqvist
Journal:  Lancet       Date:  1987-10-10       Impact factor: 79.321

Review 3.  Ethnic differences in drug metabolism.

Authors:  W Kalow
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

4.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.

Authors:  K Nakamura; F Goto; W A Ray; C B McAllister; E Jacqz; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

5.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

6.  Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.

Authors:  G Alván; P Bechtel; L Iselius; U Gundert-Remy
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.

Authors:  A Küpfer; R Preisig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Sparteine oxidation polymorphism in Denmark.

Authors:  K Brøsen; S V Otton; L F Gram
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1985-11

9.  Evidence for the polymorphic oxidation of debrisoquine in the Thai population.

Authors:  S Wanwimolruk; P Patamasucon; E J Lee
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

10.  Debrisoquine oxidation in an Australian population.

Authors:  G F Peart; J Boutagy; G M Shenfield
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335
View more
  3 in total

1.  Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) population.

Authors:  S Wanwimolruk; M R Thou; D J Woods
Journal:  Br J Clin Pharmacol       Date:  1995-08       Impact factor: 4.335

2.  Genetically determined sparteine oxidation polymorphism in a Polish population.

Authors:  K Orzechowska-Juzwenko; J Pawlik; P Niewiński; P Milejski; J Dembowski; J Turek; A Goździk; L Swiebodzki; Z Hora
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

3.  Debrisoquine hydroxylation in a Polish population.

Authors:  P K Kunicki; D Sitkiewicz; A Pawlik; V Bielicka-Sulzyc; E Borowiecka; B Gawrońska-Szklarz; R Sterna; H Matsumoto; M Radziwoń-Zaleska
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.